stocks stock market biotech

Stock Market Sells Off As Biotech Gets Rocked, Again!

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary to get the Weekly Monster Market Commentary and join the 3,071 subscribers getting it for FREE!

This Daily Commentary Is Availabe For $99 Per Year, Sign Up!

[widget id=”text-15″]

[widget id=”wordads_sidebar_widget-41″]

Stock Market Sells Off As Biotech Gets Rocked, Again!

Just more of the same isn’t? Gap up at the open, then a slow drag lower the rest of the day. I hate days were the market just gaps up, what is the point? It always just fills the gap. You must avoid opens like the one day.

Could it be more obvious? The only difference today was that we managed to fill two gaps. It’s getting old that is for sure and just serves as more of an annoyance than anything fundamentally changing.

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”] [widget id=”text-11″]

[widget id=”text-12″]

s&P 500 The real frustrating part in most of this is that the media seems to like to talk about “warnings signs,” making a bigger deal than it deserves.

Is the market “overbought?”, Technically yes, based on the relative strength index reading of 77, because a reading over 70 is considered overbought. The last time I checked the market doesn’t go up in a straight line and a pullback is expected to happen.

I have surely been one of the more aggressive bulls on Wall Street, over the past two years, and I’m looking for a rise to 3,100 in 2018 on the S&P 500. More recently I have suggested we could see a rise to roughly 2,850 by the start of March. But at the current pace, we would have likely hit that number before the end of January. So I would welcome a period of sideways consolidation or even a 2-3 percent pullback.

Subscribe to the MCM Stock Market Commentary to get it weekly and join the 3,071 subscribers getting it for FREE!

Fundamentally, the equity market is not expensive. The S&P 500 operating earnings are estimated to climb by 10.5 percent in 2019 to $164.57. That estimate, provided by Dow Jones S&P Indices, was just lifted from $160.03 on December 31. Based on that, even at 2,775 the S&P 500 is only valued at 16.8 times 2019 operating earnings. At the end of the first quarter on March 31, 2017, the S&P was trading at 16.6 times 2018 operating earnings estimates. So even with the fast start to the year, the market is valued at the same level it was last year to the start the year. Should estimates keep trending higher, then the market is only getting cheaper if the pace of earnings is climbing faster than the speed of the market.

The economy continues to strengthen with GDPNow forecasting a reading of 3.2 percent in the fourth quarter of 2017. That would make three straight quarters of GDP growth higher than 3 percent. Economies globally appear on the mend, and to this bull, things are looking pretty good.

So much for the naysayers that said that US GDP could no longer grow at 3 percent. Not to rub it in the face of the “economist”, but I did call this move higher in the economy in May of 2017. For that matter, I see a four handle coming in 2018.

[widget id=”text-13″]

Biotech Stocks

The NASDAQ Biotech ETF ($IBB) was greeted with some resistance when they got to $113.50, no surprises, right? We can see it failed at that same level back in October, and it is going to have to battle to get through resistance. But we also know there is real support around $107, and the NASDAQ IBB is far from overbought at current levels.

ibb Surprisingly, 4 of the big 5 biotech stocks held there gains, with Amgen, Biogen, Gilead, and Regeneron all up. Only Celgene was down in that group. But look at the most significant losers today, they have also been among some of the most prominent gainers year to date. Plus just breaking tonight, Celgene is looking to acquire Juno according to the Wall Street Journal. Celgene isn’t messing around in 2018, and they are working very hard at diversifying that pipeline, the market seems so obsessed about.



The air is really coming out of Roku now, and it is probably going to see a bounce back to $43, but don’t be fooled.

roku That gonna be it today.

Sign-up for our premium content on Seeking Alpha Market Place – “Reading The Markets” and a get Two Week Free Trial Period

Premium Content: Benefits include the ability to reach out to Mike with questions through a chat room, direct message, or comments.

Now JUST $25 Per Month Or $200 Per Year – Get Your Free 2-Week Trial Now!

Euro’s Big Breakout

Inflation, Tesla Plus So Much More

Predicting The Euro’s Rise

An Intelligent Way Of Looking At Tesla’s Results

3 Biotech Names To Start The Year

Disney- The Market Finally Get’s It


Free Articles Written By Mike:

Why Ford Could Rise By Nearly 30%

Why Morgan Stanley’s Stock Is Poised to Rise by 25%

Apple Poised to Gain 14%, Defying Skeptics

Exxon Mobil May Rise 20% on the Back of Surging Oil

Qualcomm’s Stock Heads to a Crossroads

We offer daily market commentaries sent directly to your inbox or follow us on Twitter.

Join our 3,071 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe


[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Photo Credit Via Flickr

Michael Kramer and the Clients of Mott Capital own shares of CELG and TSLA

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2017 Mott Capital Management, LLC. Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #sp500 #bitoech #celgene #roku #biogen #amgen #gilead